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INTRODUCTION
Heme oxygenases, particularly the
inducible heme oxygenase-1 (HO-1), are
the subject of intensive research since
they show great promise as cytoprotec-
tive agents. These enzymes degrade heme
to generate biliverdin, free iron, and car-
bon monoxide (CO), and this reaction
appears to be crucial in a number of
diverse biological systems. Decreasing free
heme in itself is beneficial [for example
in sepsis and infections (Gozzelino et al.,
2010)], but much attention is also paid
to the products of heme degradation as
biologically active agents with therapeu-
tic potential (Motterlini and Otterbein,
2010; Wegiel et al., 2012). Indeed, the
physiological roles and potential of CO in
particular (applied either by inhalation,
or via CO releasing molecules; CORMs)
are currently topics of intense research,
with clinical trials currently evaluating
its safety in human subjects and its use-
fulness in treating a variety of disorders
(http://clinicaltrials.gov/ct2/search,
bon monoxide”) (Wu and Wang, 2005;
Durante et al., 2006; Kim et al., 2006;
Ryter et al., 2006).
In this current climate of hopeful
promise for CO-based therapies, it is easy
to lose sight of the fact that it is a highly
toxic gas: CO poisoning accounts for more
than 50% of all fatal poisonings world-
wide (Meredith and Vale, 1988; Cobb and
Etzel, 1991; Varon et al., 1999). Although
the number of fatalities arising from acute
exposure may be considered relatively low,
chronic exposure can much more com-
monly produce neurological and cardio-
vascular damage (Von Burg, 1999; Gandini
et al., 2001; Omaye, 2002; Prockop and
Chichkova, 2007), particularly in the aging
population, and symptoms are often diffi-
cult to diagnose (Harper and Croft-Baker,
2004). Appropriately, therefore, much cau-
tion is taken as clinical trials progress and
as our awareness of the biological actions
of CO continues to develop.
In recent years, ion channels (and,
more recently, transporters) have emerged
as major targets for modulation by CO
(Peers, 2011; Wilkinson and Kemp, 2011;
Peers and Steele, 2012). Intriguingly, mod-
ulation of some channels by CO may
contribute to its beneficial actions, yet
the sensitivity of other channels to CO
may account, at least in part, for some
of its deleterious actions (summarized
in Figure 1). In this article, I draw
upon some recent examples of ion chan-
nel/transporter modulation by CO in the
cardiovascular and central nervous sys-
tems in order to compare the benefi-
cial and deleterious cellular effects of CO,
and to examine whether we should be
concerned about the therapeutic index
of CO.
CARDIOVASCULAR EFFECTS OF CO
In the cardiovascular system, HO-1 (most
commonly via its production of CO) exerts
multiple beneficial effects. In addition
to its known antihypertensive actions, it
appears to be involved in numerous vas-
cular diseases. Paradoxically, it suppresses
vascular smooth muscle proliferation, yet
augments endothelial proliferation, both
of which can be considered beneficial.
Suppression of smooth muscle prolifer-
ation is important in combating devel-
opment of vessel thickening associated
with vascular injury and grafting, and
also in the progression of atherosclero-
sis [reviewed by Barbagallo et al. (2012)].
Stimulation of endothelial proliferation
is dependent on vascular endothelial
growth factor (VEGF) production, and is
required for angiogenesis: HO-1 induction
or CO exposure promotes endothelial
VEGF production, proliferation, migra-
tion, and neovascularization (Jozkowicz
et al., 2003).
In the heart and coronary vasculature,
HO-1 expression can be increased by var-
ious stress factors including myocardial
infarction or ischemia/reperfusion (I/R)
(Lakkisto et al., 2002). The importance
of HO-1 is well illustrated by studies
employing transgenic mice: for exam-
ple, in heterozygote HO-1+/− KO mice
I/R caused significantly greater cardiac
damage than wild-type mice (Yoshida
et al., 2001). In HO-1−/− mice, chronic
hypoxia (which normally up-regulates
HO-1) caused significantly greater right
ventricular hypertrophy, oxidative dam-
age, and pulmonary hypertension (Yet
et al., 1999). Furthermore, cardiac-specific
overexpression of HO-1 strongly protects
against I/R damage (Yet et al., 2001) and in
a coronary ligation model of heart failure
(Wang et al., 2010).
Although HO-1 is clearly protective,
the relative contributions of heme reduc-
tion or biliverdin, Fe2+ and CO produc-
tion are not fully elucidated. However,
there is much evidence to support a
key role for CO in HO-1-mediated car-
dioprotection. For example, Wang et al.
(2010) reported that CORM-3 protected
the myocardium against adverse remod-
eling following coronary ligation to a
degree comparable with over-expression
of HO-1. Indeed, CORMs have provided
much support for the idea that HO-1
is cardioprotective via CO production.
For example, infusion of CORM-3 dur-
ing the reperfusion phase of I/R challenges
reduced myocardial damage in vitro and
in vivo (Clark et al., 2003; Guo et al., 2004),
and CORM-3 can have a positive inotropic
effect (Musameh et al., 2006).
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FIGURE 1 | Pathways contributing to the protective (green) and deleterious (red) effects of CO.
As part of a study aimed at iden-
tifying potential mechanisms accounting
for the protective effects of CO in the
myocardium, we discovered that CO could
inhibit the L-type Ca2+ current (Scragg
et al., 2008). This effect was mediated by
a CO-induced increase in ROS production
from mitochondria, which modulated the
channel via key cysteine residues located
in the intracellular C-terminal domain of
the α subunit. Inhibition of L-type Ca2+
channels would be predicted to reduce the
energy demands of the myocardium, and
hence could be considered as protective.
However, when we subsequently examined
the effects of CO and CO donors on single
cardiac myocytes, the dominant effect was
for CO to be pro-arrhythmic (Dallas et al.,
2012): early after-depolarization events
were detected via patch-clamp and Ca2+
imaging. These effects were attributable to
CO-induced increases in NO levels, which
led to an augmentation of the late compo-
nent of the Na+ current via direct nitro-
sylation of Nav1.5. Crucially, rats exposed
to 500 ppmCO displayed ECG abnormali-
ties consistent with these effects, and when
they were exposed to CO following isopre-
naline injection, ventricular fibrillation,
and death was observed. All effects were
reversed by ranolazine, a known inhibitor
of the late Na+ current (Dallas et al., 2012).
NEUROLOGICAL EFFECTS OF CO
The protective effects of CO in the
central nervous system have also been
demonstrated in a number of model sys-
tems. For example, CO inhalation (up to
250 ppm) provides clear beneficial effects
against the damage of I/R brain injury
and ischemic stroke (Wang et al., 2011;
Zeynalov and Dore, 2009). Furthermore,
pre-exposure to CO (also at 250 ppm) pro-
vided pre-conditioning protection against
neurological damage (specifically, neu-
ronal apoptosis) in a pig model of deep
hypothermic circulatory arrest, which is
a widely used technique in surgical treat-
ment of heart defects (Mahan et al., 2012).
At the cellular level, pretreatment
of primary cultures of cerebellar gran-
ule neurons with 250 ppm CO provided
protection against apoptosis induced by
oxidative stress or excitotoxic levels of
exogenous glutamate (Vieira et al., 2008).
Interestingly, protection appeared to be
comparable to the pre-conditioning asso-
ciated with sub-lethal ischemia, where
neurons become more resistant to other-
wise lethal ischemic challenges by prior
exposure to a less severe challenge. Vieira
et al. reported that protection afforded
by CO involved activation of guany-
late cyclase and subsequent activation of
mitochondrial ATP-sensitive K+ channels.
Importantly, they also reported increased
intracellular ROS levels and stimulation of
NO formation in response to CO exposure
(Vieira et al., 2008). The increase in ROS
formation is a key pre-conditioning step,
since it triggers up-regulation of protective
protein expression, including HO-1.
We subsequently provided another
mechanism to account for neuroprotec-
tive effects of CO. According to a number
of studies from Aizenman and colleagues
(Redman et al., 2007; Pal et al., 2003,
2006), a key early stage in stress-induced
neuronal apoptosis is the rapid insertion
into the plasma membrane of K+ chan-
nels, particularly Kv2.1, which leads to loss
of cytoplasmic K+ and the initiation of
apoptotic signaling. Consistent with this
hypothesis, we found that over-expression
of Kv2.1 in HEK293 cells increased sus-
ceptibility to oxidative apoptotic stimuli,
but that this could be prevented by CO
i.e., CO provided protection against apop-
tosis specifically in Kv2.1 expressing cells
(Dallas et al., 2011). Furthermore, CO
directly inhibited Kv2.1 channels, and the
currents arising from the “surge” of K+
channels in response to apoptotic stimuli.
Importantly, these effects were reproduced
in primary cultures of hippocampal neu-
rons (Dallas et al., 2011). Interestingly, a
recent study demonstrated that the CO
donor, CORM-3, provided a degree of
neuroprotection against a collagenase
injection model of hemorrhagic stroke
if administered in advance, but under
other circumstances could exacerbate the
associated damage (Yabluchanskiy et al.,
2012).
The above described data indicate that
COmay provide neuroprotection via mul-
tiple mechanisms. However, stimulation of
both ROS and NO formation (implicated
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in some protective pathways) is not with-
out risk, in part because it can lead to
formation of the highly damaging ROS
species peroxynitrite (ONOO−). Indeed,
we reported recently that such effects of
CO may account for some of the dele-
terious neurological effects of CO poi-
soning: we monitored Ca2+ homeostasis
in human neuroblastoma (SH-SY5Y) cells
and noted that exposure of cells to the
CO donor CORM-2 caused an apparent
increase in both voltage gated Ca2+ entry
and prolonged receptor-mediated rises of
[Ca2+]i arising from mobilization of Ca2+
from endoplasmic reticulum stores and
subsequent capacitative Ca2+ entry. These
potentially deleterious effects of CO were
abolished either by an antioxidant or by
inhibition of NO formation with L-NAME
(Hettiarachchi et al., 2012). NO donors
alone were unable to mimic these actions
of CO, indicating that both NO and ROS
were required for CO to disrupt Ca2+
signaling. A rise of ONOO− levels was
detected via APF fluorescence, and the
ONOO− scavenger FeTPPs also inhib-
ited the effects of CO. Mechanistically,
we reasoned that for CO to disrupt so
many Ca2+ signaling pathways it most
likely acted via modulation of a common
target protein, and we identified a CO-
dependent down regulation of the plas-
malemmal Ca2+ ATPase (PMCA) in both
SH-SY5Y cells and also in whole brain
homogenates from rats exposed to 1000 or
3000 ppm CO for 40mins (Hettiarachchi
et al., 2012).
A QUESTION OF CONCENTRATION?
The example studies cited here raise the
question of whether beneficial effects of
CO differ from deleterious effects (shown
schematically in Figure 1) simply because
of concentration, or for some other,
unidentified reasons. This is not a straight-
forward issue to resolve from the current
literature, since CO is applied by various
means (inhalation, or via CORMs), and
final concentrations at the intended sites of
action are difficult or impossible to deter-
mine accurately. Although the potential
for neurological damage arising from loss
of the PMCA was observed only at high
(>1000 ppm) levels of inhaled CO in vivo,
the cellular effects on PMCA were man-
ifest using CORM-2 at 10–30μM. Such
concentrations are comparable to other
reported effects of CO/CORMs which
have been regarded, rightly or wrongly, as
beneficial/physiological effects. Most elec-
trophysiological studies have employed
CORMs at concentrations of 1–100μM
(Peers, 2011; Wilkinson and Kemp, 2011),
often at 30μM or lower. Perhaps most
alarmingly, the pro-arrhythmic actions of
CO mediated by induction of the late Na+
current (Dallas et al., 2012) were observed
when animals inhaled 500 ppm (or cells
were exposed to 20–30μM CORM-2
or -3). Such levels have been reported in
heavy traffic or as a consequence of expo-
sure to cigarette smoke (Reboul et al.,
2012), and clinical trials are under way
employing 250 ppm (see earlier). Clearly,
as discussed by Reboul et al. (2012), the
duration of exposure to CO is critical in
determining whether its outcome is ben-
eficial or detrimental, but as new tar-
gets for modulation become realized, it is
becoming clear that a better understand-
ing (or, better, a means of determination)
of CO concentration at its sites of action
is needed before we can describe effects of
CO observed in vitro as potentially ben-
eficial or detrimental. Such information
is important in the progression of CO
therapy.
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